Guru P. Sonpavde, GU Oncology Director at Advent Health Cancer Institute, shared on X:
“Immunotherapy with atezolizumab for advanced solid tumors cancer- Largest analysis of association of immune related adverse events (irAEs) and efficacy (9521 patients across 14 studies) – Low grade irAEs associated with improved survival, while specific high grade irAEs (colitis, pneumonitis) associated with poor survival- early recognition and treatment of irAEs important.”